Preimplantation Genetic Diagnosis Market Trends, Growth, Demand, opportunities, Scope & Forecast 2022 by CMI

 In 2018, the global Preimplantation Genetic Testing (PGT) (PGS/PGD) market was valued at USD 74.72 million, with a CAGR of 6.2 per cent predicted during the forecast period. Prenatal screening and early diagnosis of chromosomal abnormalities in an embryo have altered dramatically as a result of recent technological developments. In vitro fertilisation (IVF) processing has been successful thanks to the expansion of non-invasive cell-free foetal DNA-based detection procedures as well as carrier screening panels into prenatal care. This has prompted the preimplantation detection of congenital disorders in the early phases of the IVF process, which reduces the chance of inherited chromosomal abnormalities in the foetus.

The preimplantation genetic diagnosis market was estimated at $79 million in 2016, and is predicted to grow at a CAGR of 6.14 per cent to $121 million by 2022.

Increased demand for preimplantation diagnostic and screening techniques is attributable to an increase in the occurrence of a single gene, mitochondrial, and other gene-related illnesses. According to the Florida Department of Health, nearly one out of every 28 babies in the state is diagnosed with a birth defect each year. Preimplantation Genetic Diagnosis (PGD) is used before IVF to ensure a successful outcome. PGD can be used in IVF cycles for women who have had many miscarriages or who have had a previous pregnancy with a chromosomal issue. PGD has the potential to aid couples at risk of inherited illnesses while also having a favourable impact on the market.

The idea of aneuploidy screening during PGD has improved IVF treatments. The advent of aneuploidy testing in IVF clinics has resulted in a higher rate of a successful pregnancies. A study published in the journal Fertility and Sterility in August 2018 looked at successful IVF pregnancy outcomes utilising Natera's Spectrum PGT for aneuploidy (PGT-A).

IVF treatments have improved thanks to the concept of aneuploidy screening during PGD. With the introduction of aneuploidy testing in IVF clinics, the rate of successful pregnancy has increased. In August 2018, a study looked at successful IVF pregnancy outcomes using Natera's Spectrum PGT for aneuploidy, which was published in the journal Fertility and Sterility (PGT-A).

Public entities' ethical acceptability and legal requirements stifle the adoption of PGT services, stifling growth. However, growing awareness of foetus health among couples, as well as expanded applications of PGD and Preimplantation Genetic Screening (PGS), all contribute to market growth.

In terms of revenue generation, PGT implementation for detecting chromosomal abnormalities led the market in 2018. This is subjected to the constant improvement of aneuploidy detection tools, which is very common in advanced maternal age.

In 2018, Europe led the preimplantation genetic testing market in terms of revenue generated, owing to a larger use of IVF operations due to a significant number of late pregnancy instances. Furthermore, the European PGT market is bolstered by lax aneuploidy screening laws.

Illumina Inc., Thermo Fisher Scientific Inc., Natera, Inc., Bioarray S.L., Good Start Genetics, Inc., Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; Reproductive Health Science Ltd.; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, LLC; F. Hoffmann-La Roche AG; and CombiMatr Inc. are some of the major players.